Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

Jill Samis*, Paul Lee, Donald Zimmerman, Robert J. Arceci, Meinolf Suttorp, Nobuko Hijiya

*Corresponding author for this work

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.

Original languageEnglish (US)
Pages (from-to)1332-1338
Number of pages7
JournalPediatric Blood and Cancer
Volume63
Issue number8
DOIs
StatePublished - Aug 1 2016

Keywords

  • CML
  • TKI
  • children
  • endocrine
  • growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia'. Together they form a unique fingerprint.

  • Cite this